A 16-week, Phase 2a, Single-arm, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of GSK1278863 After Switching From Recombinant Human Erythropoietin (rhEPO), in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Chronically Hyporesponsive to rhEPO
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2017
Price : $35 *
At a glance
- Drugs Daprodustat (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 22 Jun 2017 Status changed from completed to discontinued.
- 06 Jun 2016 Status changed from active, no longer recruiting to completed.